IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 687 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  »   My Preferences 
  »   Manuscript submission

 


This article has been cited by
1Destination of aminoglycoside antibiotics in the ‘post-antibiotic era’
Yoshiaki Takahashi,Masayuki Igarashi
The Journal of Antibiotics.2018;71(1)4
[DOI]
2Triple Mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives
Elliasu Y. Salifu,Clement Agoni,Fisayo A. Olotu,Mahmoud E.S. Soliman
Computational Biology and Chemistry.2020;85(1)107204
[DOI]
3Triple Mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives
M. Neethi Chandra
Computational Biology and Chemistry.2021;85(1)47
[DOI]
4Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis
Jinmeng Li,Gaoyi Yang,Qingshan Cai,Yu Wang,Yingying Xu,Ruoying Zhang,Yazhen Lang,Xinjun Cai
International Journal of Infectious Diseases.2021;110(1)179
[DOI]
5Emerging strategies in nanotechnology to treat respiratory tract infections: realizing current trends for future clinical perspectives
Minhua Chen,Zhangxuan Shou,Xue Jin,Yingjun Chen
Drug Delivery.2022;29(1)2442
[DOI]
6Mycobacterial tryptophan biosynthesis: A promising target for tuberculosis drug development?
Sara Consalvi,Cristina Scarpecci,Mariangela Biava,Giovanna Poce
Bioorganic & Medicinal Chemistry Letters.2019;29(23)126731
[DOI]
7The Emergence of Phenolic Glycans as Virulence Factors in Mycobacterium tuberculosis
Danielle D. Barnes,Mimmi L. E. Lundahl,Ed C. Lavelle,Eoin M. Scanlan
ACS Chemical Biology.2017;12(8)1969
[DOI]
8Screening of natural compounds that targets glutamate racemase of Mycobacterium tuberculosis reveals the anti-tubercular potential of flavonoids
Alka Pawar,Prakash Jha,Madhu Chopra,Uma Chaudhry,Daman Saluja
Scientific Reports.2020;10(1)1969
[DOI]
9The respiratory lipoquinone, menaquinone, functions as an inducer of genes regulated by the Mycobacterium smegmatis repressor MSMEG_2295
Anik Barman,Madhu Manti Patra,Sujoy K. Das Gupta
Microbiology.2022;168(5)1969
[DOI]
10Applicability of Chromatographic Co-Elution for Antibiotic Target Identification
Sina Schäkermann,Dominik Wüllner,Abdulkadir Yayci,Andrew Emili,Julia Elisabeth Bandow
PROTEOMICS.2021;21(1)2000038
[DOI]
11Mycobacterial protein tyrosine kinase, PtkA phosphorylates PtpA at tyrosine residues and the mechanism is stalled by the novel series of inhibitors
Swati Jaiswal,Aditi Chatterjee,Sapna Pandey,Kiran Lata,Ranjith Kumar Gadi,Rajesh Manda,Sanjay Kumar,Maddi Sridhar Reddy,Ravishankar Ramachandran,Kishore K. Srivastava
Journal of Drug Targeting.2019;27(1)51
[DOI]
12Strategies towards the synthesis of anti-tuberculosis drugs
Haridas B. Rode,Dhanaji M. Lade,René Grée,Prathama S. Mainkar,Srivari Chandrasekhar
Organic & Biomolecular Chemistry.2019;17(22)5428
[DOI]
13Impact of drug-resistant tuberculosis treatment on hearing function in South African adults: Bedaquiline versus kanamycin
Katijah Khoza-Shangase,Marina Prodromos
South African Journal of Communication Disorders.2021;68(1)5428
[DOI]
14Recent developments, challenges and future prospects in advanced drug delivery systems in the management of tuberculosis
Nitin Verma,Vimal Arora,Rajendra Awasthi,Yinghan Chan,Niraj Kumar Jha,Komal Thapa,Talha Jawaid,Mehnaz Kamal,Gaurav Gupta,Gang Liu,Keshav Raj Paudel,Philip Michael Hansbro,Brian Gregory George Oliver,Sachin Kumar Singh,Dinesh Kumar Chellappan,Harish Dureja,Kamal Dua
Journal of Drug Delivery Science and Technology.2022;68(1)103690
[DOI]
15Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations
Shalini Saxena,Maaged Abdullah,Dharmarajan Sriram,Lalitha Guruprasad
Journal of Biomolecular Structure and Dynamics.2018;36(12)3184
[DOI]
16Multitarget Approaches against Multiresistant Superbugs
Declan Alan Gray,Michaela Wenzel
ACS Infectious Diseases.2020;6(6)1346
[DOI]
17Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance
Vahid Lohrasbi,Malihe Talebi,Abed Zahedi Bialvaei,Lanfranco Fattorini,Michel Drancourt,Mohsen Heidary,Davood Darban-Sarokhalil
Tuberculosis.2018;109(6)17
[DOI]
18Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance
Fiona V. Cresswell,Abdu K. Musubire,Katarina M. Johansson Århem
Tuberculosis.2020;109(6)67
[DOI]
19Bedaquiline and delamanid in tuberculosis
Susanna Esposito,Sonia Bianchini,Francesco Blasi
Expert Opinion on Pharmacotherapy.2015;16(15)2319
[DOI]
20An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004–2018)
Mahanjit Konwar,MiteshR Maurya,TusharB Nishandar,UrmilaM Thatte,NithyaJ Gogtay
Perspectives in Clinical Research.2021;12(3)159
[DOI]
21A review of current and promising nontuberculous mycobacteria antibiotics
Christophe R Cantelli,Alexandra Dassonville-Klimpt,Pascal Sonnet
Future Medicinal Chemistry.2021;13(16)1367
[DOI]
22A structure-based strategy toward the development of novel candidates for antimycobacterial activity: Synthesis, biological evaluation, and docking study
Linhu Li,Yuanyuan Jin,Bin Wang,Zhaoyong Yang,Mingliang Liu,Huiyuan Guo,Jun Zhang,Yu Lu
Chemical Biology & Drug Design.2018;91(3)769
[DOI]
23New Ways to Treat Tuberculosis Using Dendrimers as Nanocarriers
Serge Mignani,Rama Tripathi,Liang Chen,Anne-Marie Caminade,Xiangyang Shi,Jean-Pierre Majoral
Pharmaceutics.2018;10(3)105
[DOI]
24Two Decades of TB Drug Discovery Efforts—What Have We Learned?
Balachandra Bandodkar,Radha Krishan Shandil,Jagadeesh Bhat,Tanjore S. Balganesh
Applied Sciences.2020;10(16)5704
[DOI]
25AN INSIGHT INTO PRIVILEGED SCAFFOLDS IN TUBERCULOSIS: DEVELOPMENTAL ASPECTS AND IMPLICATIONS IN DRUG DESIGN
Rani. A. Shinde,Vasanti. M. Suvarna,Arundhati. N. Abhyankar
Indian Drugs.2022;59(01)7
[DOI]
26Nanotechnology as a Novel Approach in Combating Microbes Providing an Alternative to Antibiotics
Bismillah Mubeen,Aunza Nayab Ansar,Rabia Rasool,Inam Ullah,Syed Sarim Imam,Sultan Alshehri,Mohammed M. Ghoneim,Sami I. Alzarea,Muhammad Shahid Nadeem,Imran Kazmi
Antibiotics.2021;10(12)1473
[DOI]
27Discovery and Development of Antibacterial Agents: Fortuitous and Designed
Ravleen Kaur,Pooja Rani,Atanas G. Atanasov,Qushmua Alzahrani,Reena Gupta,Bhupinder Kapoor,Monica Gulati,Pooja Chawla
Mini-Reviews in Medicinal Chemistry.2022;22(7)984
[DOI]
28Discovery and Development of Antibacterial Agents: Fortuitous and Designed
Corliss A. O’Bryan,Philip G. Crandall,Steven C. Ricke
Mini-Reviews in Medicinal Chemistry.2018;22(7)99
[DOI]
29Inhibition of Mycobacterium tuberculosis InhA: Design, synthesis and evaluation of new di-triclosan derivatives
Tom Armstrong,Malcolm Lamont,Alice Lanne,Luke J. Alderwick,Neil R. Thomas
Bioorganic & Medicinal Chemistry.2020;28(22)115744
[DOI]
30The antimicrobial and immunomodulatory effects of Ionophores for the treatment of human infection
Gen Li,David M.P. De Oliveira,Mark J. Walker
Journal of Inorganic Biochemistry.2022;227(22)111661
[DOI]
31Chitosan nanoparticles as a promising approach for pulmonary delivery of bedaquiline
Tejal Rawal,Snehal Patel,Shital Butani
European Journal of Pharmaceutical Sciences.2018;124(22)273
[DOI]
32A Test System for in vitro Screening Antimycobacterial Drug Candidates for MmpS5-MmpL5 Mediated Resistance
K. V. Shur,S. G. Frolova,N. I. Akimova,V. N. Danilenko,D. A. Maslov
Russian Journal of Genetics.2021;57(1)114
[DOI]
33Nontuberculous Mycobacterial Resistance to Antibiotics and Disinfectants: Challenges Still Ahead
Samira Tarashi,Seyed Davar Siadat,Abolfazl Fateh,Fu-Ming Tsai
BioMed Research International.2022;2022(1)1
[DOI]
34Bedaquiline: A Mini Review
Nandhini Saravanabavan,Padmavathi Shanmuganathan,Manimekalai Kumarappan
Annals of SBV.2020;8(1)2
[DOI]
35Synthesis, Characterization, Molecular Docking Studies and Biological Evaluation of Some Conjugated Quinazoline-Sulfonamide Scaffold
A. Sunil Kumar,Jyothi Kudva,B. R. Bharath,Vaishali M Rai,S. Madan Kumar,Vasantha Kumar,Shyama Prasad Sajankila
ChemistrySelect.2018;3(48)13586
[DOI]
36Efflux pumps in Mycobacterium tuberculosis and their inhibition to tackle antimicrobial resistance
Mark Laws,Peiqin Jin,Khondaker Miraz Rahman
Trends in Microbiology.2022;30(1)57
[DOI]
37Knowledge Gaps in the Understanding of Antimicrobial Resistance in Canada
Kayley D. McCubbin,R. Michele Anholt,Ellen de Jong,Jennifer A. Ida,Diego B. Nóbrega,John P. Kastelic,John M. Conly,Matthias Götte,Tim A. McAllister,Karin Orsel,Ian Lewis,Leland Jackson,Graham Plastow,Hans-Joachim Wieden,Kathy McCoy,Myles Leslie,Joan L. Robinson,Lorian Hardcastle,Aidan Hollis,Nicholas J. Ashbolt,Sylvia Checkley,Gregory J. Tyrrell,André G. Buret,Elissa Rennert-May,Ellen Goddard,Simon J. G. Otto,Herman W. Barkema
Frontiers in Public Health.2021;9(1)57
[DOI]
38The effect of surgery on the outcome of treatment for multidrug-resistant tuberculosis: a systematic review and meta-analysis
Rebecca C. Harris,Mishal S. Khan,Laura J. Martin,Victoria Allen,David A. J. Moore,Katherine Fielding,Louis Grandjean
BMC Infectious Diseases.2016;16(1)57
[DOI]
39Hit Compounds and Associated Targets in Intracellular Mycobacterium tuberculosis
Clement K. M. Tsui,Flavia Sorrentino,Gagandeep Narula,Alfonso Mendoza-Losana,Ruben Gonzalez del Rio,Esther Pérez Herrán,Abraham Lopez,Adama Bojang,Xingji Zheng,Modesto Jesus Remuiñán-Blanco,Yossef Av-Gay
Molecules.2022;27(14)4446
[DOI]
40Early Drug Development and Evaluation of Putative Antitubercular Compounds in the -Omics Era
Alina Minias,Lidia Zukowska,Ewelina Lechowicz,Filip Gasior,Agnieszka Knast,Sabina Podlewska,Daria Zygala,Jaroslaw Dziadek
Frontiers in Microbiology.2021;11(14)4446
[DOI]
Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow